Aclaris Therapeutics (NASDAQ:ACRS) Announces Quarterly Earnings Results

Aclaris Therapeutics (NASDAQ:ACRS) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03), Zacks reports. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The company had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million.

Aclaris Therapeutics Stock Up 7.8 %

ACRS stock opened at $2.64 on Friday. The business has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.26. The stock has a market cap of $188.36 million, a price-to-earnings ratio of -3.22 and a beta of 0.10. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $5.61.

Analysts Set New Price Targets

Several analysts recently weighed in on ACRS shares. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.